Article

Immunogenicity of the third and fourth BNT162b2 mRNA COVID-19 boosters and factors associated with immune response in systemic lupus erythematosus and rheumatoid arthritis patients

2022-03-15

Abstract excerpt

<h4>Objectives</h4> To evaluate the safety and immunogenicity of third and fourth BNT162b2 boosters in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients. <h4>Methods</h4> SLE and RA patients aged 18-65 years who completed a series of inactivated, adenoviral vector, or heterogenous adenoviral vector/mRNA vaccines for at least 28 days were enrolled. Immunogenicity assessment was done before a...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: d9f07a0b-a6d7-5dcb-b5de-4bec2066a4c8
DOI: 10.1101/2022.03.15.22272350

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Immunogenicity of the third and fourth BNT162b2 mRNA COVID-19 boosters and factors associated with immune response in systemic lupus erythematosus and rheumatoid arthritis patientsDOI 10.1101/2022.03.15.22272350Read

Immunogenicity and clinical outcomes of booster mRNA vaccine BNT162b2 in primary antibody deficienciesSemantic proximity Read

BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in Systemic Lupus ErythematosusSemantic proximity Read

Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boostersSemantic proximity Read

Immune responses and disease biomarker long-term changes following COVID-19 mRNA vaccination in a cohort of rheumatic disease patientsSemantic proximity Read

ASIA syndrome after BNT162b2 vaccination: Is it a distinct rheumatoid arthritis phenotype?Semantic proximity Read

Immunogenicity and Safety of the Booster BNT162b2 Vaccine in Patients with Axial Spondyloarthritis Treated with Biological Disease-Modifying DrugsSemantic proximity Read

Neutralizing Activities against the Omicron Variant after a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac VaccinationSemantic proximity Read

Systems biological assessment of human immunity to BNT162b2 mRNA vaccinationSemantic proximity Read

A boost with SARS-CoV-2 BNT162b2 mRNA vaccine elicits strong humoral responses independently of the interval between the first two dosesSemantic proximity Read

Ten cases with ASIA syndrome after BNT162b2 vaccination: Is it a distinct rheumatoid arthritis phenotype?Semantic proximity Read

Immune defects associated with lower SARS-CoV-2 BNT162b2 mRNA vaccine response in aged peopleSemantic proximity Read

Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trialSemantic proximity Read